Role of PI3K signalling in canine myxomatous mitral valve disease (MMVD)
dc.contributor.advisor
Corcoran, Brendan
dc.contributor.advisor
MacRae, Victoria
dc.contributor.advisor
Phadwal, Kanchan
dc.contributor.author
Tang, Qiyu
dc.contributor.sponsor
China Scholarship Council
en
dc.contributor.sponsor
CavalierHealth.org
en
dc.contributor.sponsor
Canine Health Foundation
en
dc.contributor.sponsor
American Kennel Club (AKC)
en
dc.date.accessioned
2024-07-09T10:20:59Z
dc.date.available
2024-07-09T10:20:59Z
dc.date.issued
2024-07-09
dc.description.abstract
Myxomatous mitral valve disease (MMVD) represents a predominant cardiac
valvular pathology in both humans and canines, serving as a principal
contributor to substantial morbidity and mortality across these species.
Presently, therapeutic options to prevent, decelerate, or ameliorate the valvular
degeneration attributed to MMVD are nonexistent. Consequently, an
augmented comprehension of MMVD's pathogenetic mechanisms is
imperative to facilitate the innovation of new therapeutic approaches for this
condition in both humans and canines.
The objective of this study was to elucidate the involvement of
phosphoinositide 3-kinase (PI3K) signalling in the pathogenesis of canine
MMVD by delineating the molecular dynamics governing the pathological
phenotypic transition of valve interstitial cells (VICs) and related cellular
processes within a 2D VIC culture system derived from clinical samples. High
expression levels of transforming growth factor-β1 (TGF-β1) and PI3K were
identified in myxomatous mitral valve tissues. Activation of the
PI3K/AKT/mTOR pathway and an upsurge in TGF-β expressions were
observed in cultured activated myofibroblasts (aVICs). TGF-β1 facilitated the
conversion of quiescent VICs (qVICs) to aVICs through the enhancement of
PI3K/AKT/mTOR signalling. Counteracting PI3K/AKT/mTOR signalling
mitigated the myofibroblast transformation of aVICs by suppressing cellular
senescence and fostering autophagy. Augmentation of mTOR/S6K signalling
prompted the transition of senescent aVICs, characterized by a diminished
propensity for apoptosis and autophagy. Targeted silencing of p70 S6K
(RPS6KB1) mitigated cellular transition by reducing senescence, curtailing
apoptosis, and augmenting autophagy. Hence, TGF-β-induced
PI3K/AKT/mTOR signalling was implicated in MMVD development,
significantly influencing myofibroblast differentiation, apoptosis, autophagy,
and senescence within the context of MMVD.
Next senescent aVICs were found to exhibit impaired autophagy as evidenced
by compromised autophagy flux and immature autophagosomes.
mTOR-dependent autophagy induced by rapamycin attenuated cell
senescence and promoted the translocation of cyclin-dependent kinase
inhibitors (CDKIs) p16INK4A (CDKN2A) and p21CIP1 (CDKN1A) from the nucleus
to the cytoplasm. Furthermore, induction of autophagy by autophagy-related
(ATG) gene overexpression restored autophagy flux and reduced p16INK4A and
p21CIP1 expression and senescence-associated secretory phenotype (SASP).
Conversely, autophagy deficiency induced p16INK4A and p21CIP1 accumulation
and SASP, and ATG re-expression alleviated senescent phenotypic
transformation, observed in both VICs and HEK293T cells. Notably, p16INK4A
and p21CIP1 localized to autophagosomes and lysosomes after rapamycin
treatment. p62/SQSTM1 was screened out as the autophagy receptor to
selectively sequestrate p16INK4A and p21CIP1 cargoes for autophagic
degradation.
Finally canine induced pluripotent stem cells (ciPSCs) were developed in order
to further investigate the important role of autophagy in stemness, senescence
and cell differentiation of VICs.
To conclude, aberrant activation of TGF-β induced PI3K signalling may drive
the transformation of senescent aVICs from qVICs, SASP induction and
autophagy impairment. Deficient autophagy in VICs accumulates CDKI
p16INK4A and p21CIP1 and induces cell senescence. Activation of autohagy
reverses senescent myofibroblast transformation and restores cellular function.
These data will inform the development of therapeutic strategies for the
treatment of MMVD in the dog and human, and for and for the management of
other age-related degenerative disorders.
en
dc.identifier.uri
https://hdl.handle.net/1842/41966
dc.identifier.uri
http://dx.doi.org/10.7488/era/4689
dc.language.iso
en
en
dc.publisher
The University of Edinburgh
en
dc.relation.hasversion
Tang Q, Markby GR, MacNair AJ, Tang K, Tkacz M, Parys M, Phadwal K, MacRae VE, Corcoran BM. (2023). TGF-β-induced PI3K/AKT/mTOR pathway controls myofibroblast differentiation and secretory phenotype of valvular interstitial cells through the modulation of cellular senescence in a naturally occurring in vitro canine model of myxomatous mitral valve disease. Cell Prolif. 4:e13435
en
dc.relation.hasversion
Phadwal K, Tang Q, Luijten I, Zhao JF, Corcoran B, Semple RK, et al. (2023). p53 Regulates Mitochondrial Dynamics in Vascular Smooth Muscle Cell Calcification. Int. J. Mol. Sci. 13;24(2):1643
en
dc.relation.hasversion
McNair AJ, Markby GR, Tang Q, MacRae VE, Corcoran BM. (2023). TGF-β phospho antibody array identifies altered SMAD2, PI3K/AKT/SMAD, and RAC signalling contribute to the pathogenesis of myxomatous mitral valve disease. Front. Vet. Sci. Oct 16;10:1202001.
en
dc.relation.hasversion
Tang Q, McNair AJ, Phadwal K, Macrae VE and Corcoran BM. (2022). The Role of Transforming Growth Factor-β signalling in Myxomatous Mitral Valve Degeneration. Front. Cardiovasc. Med. 9:872288
en
dc.relation.hasversion
Phadwal K, Koo E, Jones RA, Forsythe RO, Tang K, Tang Q, Corcoran BM, Caporali A, MacRae VE. (2022). Metformin protects against vascular calcification through the selective degradation of Runx2 by the p62 autophagy receptor. J. Cell Physiol. 237(11):4303-4316
en
dc.subject
Myxomatous mitral valve disease
en
dc.subject
MMVD
en
dc.subject
PI3K signalling
en
dc.subject
valve interstitial cells
en
dc.subject
TGF-β signaling
en
dc.subject
canine MMVD
en
dc.title
Role of PI3K signalling in canine myxomatous mitral valve disease (MMVD)
en
dc.title.alternative
The role of PI3K signalling in canine myxomatous mitral valve disease (MMVD)
en
dc.type
Thesis or Dissertation
en
dc.type.qualificationlevel
Doctoral
en
dc.type.qualificationname
PhD Doctor of Philosophy
en
Files
Original bundle
1 - 1 of 1
- Name:
- Tang2024.pdf
- Size:
- 18.55 MB
- Format:
- Adobe Portable Document Format
- Description:
This item appears in the following Collection(s)

